| Recruiting | Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-in NCT07002099 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Not Yet Recruiting | CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors NCT06647329 | Mingzhi Zhang | Phase 1 |
| Unknown | A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of C NCT06148220 | Huashan Hospital | N/A |
| Completed | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocyt NCT05775406 | Kymera Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With R NCT05773040 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techn NCT04417803 | Centre Hospitalier Universitaire Dijon | N/A |
| Completed | A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed NCT03128164 | Hutchison Medipharma Limited | Phase 1 |
| Completed | tTF-NGR Phase I Study NCT02902237 | University Hospital Muenster | Phase 1 |
| Completed | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lym NCT02740270 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT NCT02786485 | Bellicum Pharmaceuticals | Phase 1 |
| Completed | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas NCT02661542 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 1 / Phase 2 |
| Completed | Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors NCT02211755 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 NCT02169791 | Northside Hospital, Inc. | Phase 2 |
| Terminated | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 NCT02096341 | EpicentRx, Inc. | Phase 1 |
| Unknown | CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) NCT02274584 | Peking University | Phase 1 / Phase 2 |
| Completed | Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. NCT02452099 | Maria Sklodowska-Curie National Research Institute of Oncology | N/A |
| Completed | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas NCT01851369 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas NCT01828008 | Han weidong | — |
| Unknown | Bronchoscopic Sampling Techniques in Sarcoidosis NCT01836822 | Medical University of Warsaw | N/A |
| Withdrawn | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphom NCT01490047 | Ludwig Institute for Cancer Research | Phase 1 |
| Unknown | Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling NCT01784185 | Medical University of Warsaw | N/A |
| Completed | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced NCT02048488 | Tesaro, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas NCT01512758 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects NCT01359982 | EpicentRx, Inc. | Phase 1 |
| Completed | Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction NCT01273155 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. NCT01237236 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval NCT01525394 | Eisai Inc. | Phase 1 |
| Completed | Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting NCT01387841 | Bharath Charitable Cancer Hospital and Institute | Phase 2 |
| Completed | Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO NCT01031641 | National Cancer Institute (NCI) | — |
| Completed | Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncolo NCT02140736 | Hospira, now a wholly owned subsidiary of Pfizer | — |
| Terminated | T-cell Depleted Alternative Donor Transplantation NCT00968864 | Wake Forest University Health Sciences | Phase 2 |
| Completed | A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lym NCT02578316 | Eisai Inc. | Phase 1 |
| Completed | Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Ly NCT00788099 | PharmaMar | Phase 1 |
| Completed | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy NCT00796562 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or NCT00947739 | New Mexico Cancer Research Alliance | Phase 1 |
| Completed | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma NCT00725634 | AVEO Pharmaceuticals, Inc. | Phase 1 |
| Completed | Assess the Oral Bioavailability of New ABT-263 Formulations NCT00743028 | Abbott | Phase 1 |
| Unknown | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas NCT00592163 | Alaunos Therapeutics | Phase 1 |
| Completed | Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas NCT00553189 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Collection of Tissue Samples for Cancer Research NCT00900198 | National Cancer Institute (NCI) | — |
| Completed | Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma NCT00396864 | Celgene | Phase 1 |
| Completed | Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas NCT00389077 | AEterna Zentaris | Phase 2 |
| Completed | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Re NCT00222443 | University of Oklahoma | Phase 1 |
| Terminated | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopo NCT00513318 | University of California, San Francisco | — |
| Terminated | Post Transplant Donor Lymphocyte Infusion NCT00167180 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphom NCT00152126 | St. Jude Children's Research Hospital | N/A |
| Terminated | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas NCT00023166 | Enzon Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions NCT00006518 | National Cancer Institute (NCI) | — |
| Unknown | R Retreatment in 1st Relapsed DLBCL NCT00980304 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| No Longer Available | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Trans NCT01200017 | Christopher Dvorak | — |
| Withdrawn | Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours NCT01194193 | AstraZeneca | Phase 1 |